Junyuan Tang

Title: Innovations of Junyuan Tang in Proteolysis-Targeting Chimeras

Introduction

Junyuan Tang is an accomplished inventor based in Guangdong, China. He has made significant contributions to the field of proteolysis-targeting chimeras (PROTACs). His innovative work focuses on developing molecules that can effectively target and degrade specific proteins within cells.

Latest Patents

Junyuan Tang holds a patent for a "Proteolysis-targeting chimera molecule and preparation method and use thereof." This patent discloses a PROTAC molecule that includes a ligand for a target protein, specifically a pyridine carboxylic acid-1-oxide derivative. In experimental studies involving cells and zebrafish, the PROTAC molecule demonstrated no toxic or side effects at concentrations that achieve the desired therapeutic effect. Notably, the molecule inhibits human tyrosinase (TYR) at a concentration of less than or equal to 1 μmol/L. This innovation significantly reduces melanin production by degrading TYR, showcasing excellent solubility, safety, efficacy, and a low effective concentration.

Career Highlights

Junyuan Tang is affiliated with Guangzhou Medical University, where he continues to advance his research in the field of molecular biology and drug development. His work has the potential to impact therapeutic strategies for conditions related to melanin production and other protein-related disorders.

Collaborations

Junyuan Tang collaborates with notable colleagues, including Du Feng and Wei Yi, who contribute to his research endeavors and enhance the scope of his projects.

Conclusion

Junyuan Tang's innovative work in the development of PROTAC molecules represents a significant advancement in targeted protein degradation. His contributions to the field are poised to influence future therapeutic approaches and improve treatment outcomes.